An announcement from CAMP4 Therapeutics Corporation ( (CAMP) ) is now available.
On March 12, 2025, CAMP4 Therapeutics Corporation announced the appointment of Douglas Williams, PhD, as a Class I director and Murray Stewart, DM FRCP, as a Class II director, effective March 17, 2025. The board expanded from ten to twelve members to accommodate these appointments. Dr. Williams, with extensive experience in executive roles within the biotechnology industry, will also join the Audit Committee. Dr. Stewart brings a wealth of biopharmaceutical leadership experience, particularly in research, clinical development, and regulatory strategy. Both directors were granted stock options and cash retainers under the company’s compensation policy, with no prior transactions or arrangements influencing their appointments.
More about CAMP4 Therapeutics Corporation
YTD Price Performance: 8.92%
Average Trading Volume: 71,223
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $111.9M
See more data about CAMP stock on TipRanks’ Stock Analysis page.